Understanding how pneumonia affects heart and lung health over time
Long-term Alterations of Host-microbiome Interactions and Cardiovascular and Respiratory Diseases Progression After Pneumonia - the HOMI-LUNG Project - Hospital-Acquired-Pneumonia
This study looks at how hospital-acquired pneumonia affects heart and lung health over time to help understand the long-term risks for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 40 Years to 80 Years |
| Sex | All |
| Sponsor | Nantes University Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 5 sites (Angers and 4 other locations) |
| Trial ID | NCT06602934 on ClinicalTrials.gov |
What this trial studies
The HOMI-LUNG - HAP project investigates the long-term effects of hospital-acquired pneumonia on cardiovascular and respiratory diseases. It aims to quantify the burden of cardiovascular disease following pneumonia and evaluate patients' acceptance of health changes. The study will also identify different pneumonia endotypes linked to cardiovascular disease exacerbation. Various assessments, including blood samples, imaging, and exercise tests, will be conducted to gather comprehensive data on the participants' health.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 40 and older with either acute cardiac disease, chronic cardiovascular disease, or those at risk of cardiovascular disease without a personal history.
Not a fit: Patients under 40 years old or those without any cardiovascular risk factors or history of pneumonia may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment strategies for patients recovering from pneumonia, particularly regarding their cardiovascular health.
How similar studies have performed: While the specific approach of this study may be novel, previous research has indicated a connection between respiratory infections and cardiovascular disease, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Group A (patients with acute cardiac disease) * Male or female * Age ≥ 40years old * Hospitalized for acute coronary syndrome for less than 7 days. * Informed consent from the patient * Person insured under a health insurance scheme Group B (patients with chronic cardiovascular disease) * Male or female, * Age ≥ 40 years old * Undergoing coronary artery by-pass surgery * Hospitalized in intensive care unit for \> 12 hours * Informed consent from the patient * Person insured under a health insurance scheme Group C (patients at risk of CVRD without chronic cardiovascular disease) * Male or female, * Age ≥ 40 years old * Familial high levels of cholesterol or triglycerides * With no personal history of CVRD, with a recent negative cardiac exercise test (last test inferior to 12 months) * Follow-up for lipid abnormalities at high risk of CVRD events * Informed consent from the patient * Person insured under a health insurance scheme Group D (patients with HAP) * Male or female * Age ≥ 40years old * With one or more risk factors for CVD among: smoking, abnormal lipidic levels, high blood pressure, obesity, diabetes mellitus, chronic kidney disease * Cured from mechanically ventilated HAP during the current hospitalization * Informed consent from the patient or relatives * Person insured under a health insurance scheme Exclusion Criteria: * o Groups A, B, C and D * Age \>80 years old * Immunosuppression pre-existing to the index hospitalisation, defined as lymphopenia \< 500 elements/mm3, haematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug. * Pregnant women, breastfeeding women. * Adults under guardianship or trusteeship. * Low probability of survival at day 28. o Groups A, B, C * Community-acquired pneumonia or Hospital-acquired pneumonia within the last year.
Where this trial is running
Angers and 4 other locations
- Angers University Hospital — Angers, France (Not_yet_recruiting)
- Nantes University Hospital — Nantes, France (Recruiting)
- Rennes University Hospital — Rennes, France (Not_yet_recruiting)
- Rouen University Hospital — Rouen, France (Not_yet_recruiting)
- Toulouse University Hospital — Toulouse, France (Not_yet_recruiting)
Study contacts
- Study coordinator: Antoine ROQUILLY
- Email: Antoine.roquilly@univ-nantes.fr
- Phone: +33253482840
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.